Another study conducted by Unome et al. [109] showed that a high post-treatment serum ALB–BIL grade change was a factor that was independently associated with worse OS in HCC patients receiving molecular targeted therapy with atezolizumab and bevacizumab. Here, ALB is linked to hepatocellular carcinoma.